611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors

J.B.A.G. Haanen, Andréas Mackensen, C. Schultze-Florey, Winfried Alsdorf, E. Wagner-Drouet, Daniel Heudobler, P. Borchmann, Antonia Busse, Stephan Mielke, Sander Bins, Guy Ungerechts, Carsten Bokemeyer, Sebastian Klobuch, Nadine Kutsch, Fabian Müller, A. Desuki, W. Zhong, L. Preussner, Ö. Türeci, Uğur Şahin